1. Home
  2. PENG vs CDNA Comparison

PENG vs CDNA Comparison

Compare PENG & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Penguin Solutions Inc. Ordinary Shares

PENG

Penguin Solutions Inc. Ordinary Shares

HOLD

Current Price

$56.51

Market Cap

2.8B

Sector

Technology

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$22.77

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PENG
CDNA
Founded
1988
1998
Country
United States
United States
Employees
2900
N/A
Industry
Semiconductors
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
1.1B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
PENG
CDNA
Price
$56.51
$22.77
Analyst Decision
Strong Buy
Buy
Analyst Count
9
6
Target Price
$27.78
$28.00
AVG Volume (30 Days)
3.2M
583.8K
Earning Date
04-01-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.05
Revenue
N/A
$48,324,000.00
Revenue This Year
$14.55
$16.01
Revenue Next Year
$16.14
$11.31
P/E Ratio
$87.50
$455.40
Revenue Growth
N/A
18.93
52 Week Low
$16.04
$10.96
52 Week High
$55.65
$23.24

Technical Indicators

Market Signals
Indicator
PENG
CDNA
Relative Strength Index (RSI) 81.95 65.92
Support Level $19.31 $15.80
Resistance Level N/A $22.89
Average True Range (ATR) 4.32 0.95
MACD 0.44 0.11
Stochastic Oscillator 81.56 90.52

Price Performance

Historical Comparison
PENG
CDNA

About PENG Penguin Solutions Inc. Ordinary Shares

Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: